12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Company News  |  Other News

ViaCyte, California Institute for Regenerative Medicine (CIRM), Juvenile Diabetes Research Foundation International (JDRF) endocrine/metabolic news

CIRM and JDRF each awarded ViaCyte an additional $3 million to support IND-enabling research with VC-01. ViaCyte plans to begin clinical testing in 2014 for VC-01 to treat Type I diabetes. VC-01 comprises ViaCyte's PEC-01 cells, which are human embryonic stem cells (hESCs)-derived pancreatic progenitor cells, encapsulated...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >